The National Comprehensive Cancer Network published its first-ever treatment guidelines for children with a solid tumor cancer type in the United States.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
